Compare Moderna, Inc. (MRNA) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Prudential Financial Inc — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Prudential Financial Inc trades at $117.2 (market cap $40.97B). The key difference: Prudential Financial Inc is the larger of the two by market cap, and Prudential Financial Inc pays a 4.75% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PRU | |
|---|---|---|
Market Cap | $23.60B | $40.97B |
Sector | Health | Financials |
52-Week High | $81.80 | $119.07 |
52-Week Low | $22.36 | $92.00 |
Enterprise Value | $19.70B | $68.03B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Prudential Financial (PRU) trades at $118.59, down 0.4% with mixed technical signals showing bullish moving averages but neutral oscillators. The company demonstrates solid fundamentals with a P/E of 12.15, net income margin of 5.5%, and consistent earnings beats in recent quarters. Recent business developments include expanding retirement offerings and international growth initiatives, supported by strong cash flow generation of $6.27B from operations in 2025.
PRU presents a compelling value opportunity with attractive valuation metrics and steady profitability, though analyst sentiment remains cautious with 68% hold ratings. Key risks include significant investing outflows and debt levels, while catalysts include upcoming Q2 earnings and continued retirement market expansion. The stock trades above consensus price targets, suggesting limited near-term upside potential despite fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
